## Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) An indole compound represented by the formula (I), or a pharmaceutically acceptable salt, solvate, or prodrug thereof;




(I)

wherein ;

$R_1$ is ~~selected from groups (a), (b), and~~ (c) wherein;

~~(a) is $C_7$-$C_{20}$ alkyl, $C_7$-$C_{20}$ haloalkyl, $C_7$-$C_{20}$ alkenyl, $C_7$-$C_{20}$ alkynyl, carbocyclic radical, or heterocyclic radical, or~~

~~(b) is a member of (a) substituted with one or more independently selected non-interfering substituents; or~~

(c) is the group -($L_1$)-$R_{11}$; where, -($L_1$)- is an alkylene chain of 1 to 8 carbon atoms and where $R_{11}$ ~~is a group selected from (a) or (b)~~ is $-(CH_2)_m$-$R_{12}$; wherein m is an integer from 0 to 2; and $R_{12}$ is the group




represented by the formula:

where n is an integer from 0 to 2 and p is an integer from 0 to 2; and $R_{13}$ is selected from $C_1$ to $C_8$ alkyl;

$R_2$ is hydrogen, or C1-C4 alkyl;

R3 is -(L3)- Z, where -(L3)- is a ~~divalent linker group selected from a~~ bond ~~or:~~



~~-CH2-~~

and Z is a group represented by the formulae,



wherein, X is oxygen ~~or sulfur~~; and $R_a$ is selected from hydrogen, $C_1$-$C_8$ alkyl, aryl, $C_1$-$C_8$ alkaryl, $C_1$-$C_8$ alkoxy, aralkyl and -CN;

R4 is the group, -($L_h$)-(hydroxyfunctional amide); wherein -($L_h$)-, is ~~an hydroxyfunctional amide linker having an hydroxyfunctional amide linker length of 1 to 8~~represented by the formula



$Q_2$ is O;

$R^{40}$ is independently selected from hydrogen and $C_1$-$C_8$ alkyl;

(Hydroxyfunctional amide) is the group



wherein $R^{4a}$ a is OH;

$R^{4b}$ is selected from the group consisting of H and $C_1$-$C_8$ alkyl;

$R_5$ is ~~selected from~~ hydrogen~~, a non-interfering substituent, or the group, -($L_a$)-(acidic group), wherein -($L_a$)-, is an acid linker having an acid linker length of 1 to 8~~; and

$R_6$ and $R_7$ are independently selected from the group consisting of hydrogen, $C_1$-$C_6$ alkyl, $C_2$-$C_6$ alkenyl, and $C_2$-$C_6$ alkynyl.

2. (Cancelled)

3. (Cancelled)

4. (Currently Amended) The compound of Claim 1 wherein the hydroxyfunctional amide linker group, -(Lh)-, for $R_4$ is a divalent group selected from,



or



~~where $R_{40}$, $R_{41}$, $R_{42}$, and $R_{43}$ are each independently selected from hydrogen, $C_1$-$C_8$ alkyl~~.

5. (Cancelled)

6. (Cancelled)

7. (Cancelled)

8. (Cancelled)

9. (Cancelled)

10. (Cancelled)

11. (Cancelled)

12. (Cancelled)

13. (Cancelled)

14. (Cancelled)

15. (Cancelled)

16. (Cancelled)

17. (Cancelled)

18. (Currently Amended) The compound of claim 1 wherein R4 is the group, ~~-($L_e$)-(hydroxyfunctional-~~($L_h$)-(hydroxyfunctional amide group) and wherein the (hydroxyfunctional amide group) is:




and $R^{4a}$ is independently selected from the group consisting of OH~~, ($C_1$-$C_6$)alkoxy, ($C_7$-$C_{14}$)alkaryloxy, ($C_2$-$C_8$)alkenyloxy, ($C_7$-$C_{14}$)-aralkyloxy, ($C_7$-$C_{14}$)aralkenyloxy and aryloxy~~; and

wherein $R^{4b}$ is ($C_1$-$C_6$)alkyl.

~~wherein $R^{4b}$ is independently selected from the group consisting of H, ($C_1$-$C_6$)alkyl, arylalkyl, heteroaryl and aryl.~~

19. (Cancelled)

20. (Previously Presented) A compound selected from the group of:

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(hydroxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(methyloxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(methyl)-*N*-(methyloxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(hydroxy)-*N*-(methyl)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(ethyloxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(2-propenyloxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(hydroxy)-*N*-(2-propyl)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(tert-butyloxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-[2-(methyl)propyloxy]acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(phenylmethyloxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(methyl)-*N*-(phenylmethyloxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(phenyloxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(methyl)-*N*-(phenyloxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(cyclohexyl)-*N*-(hydroxy)acetamide; and

2-[[3-(2-Amino-2-oxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(hydroxy)acetamide.

21. (Cancelled)

22. (Original) A pharmaceutical formulation comprising a indole compound as claimed in claim 1 together with a pharmaceutically acceptable carrier or diluent therefor.

23. (Cancelled)

24. (Cancelled)

25. (Previously Presented) A pharmaceutical formulation containing an effective amount of the compound of claim 1 useful for the treatment and/or amelioration of Inflammatory Diseases.

26. (Cancelled)

27. (Cancelled)